Prelude loses CMO, pauses SMARCA2 degraders and bags $60M from Incyte
It’s all change at Prelude Therapeutics. The precision oncology biotech is waving goodbye to its chief medical officer, pausing work on SMARCA2 degraders and selling a licensing option to Incyte…